by Alex Kadhim
Researchers at Bambino Gesù Children’s Hospital in Rome have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed or refractory acute myeloid leukemia, and that...
by Alex Kadhim
Researchers at Memorial Sloan Kettering Cancer Center and City of Hope, together with a multicenter U.S. team and Poseida Therapeutics, have reported early clinical activity for a...
by Alex Kadhim
Researchers at Imperial College London and the University of Oxford have found a bispecific CD19 and CD133 chimeric antigen receptor (CAR) engineered into invariant natural killer T cells can...
by Alex Khadhim
Researchers at Friedrich-Alexander-Universität Erlangen–Nürnberg and Universitätsklinikum Erlangen have found that autologous CD19 CAR T cell therapy can induce rapid, drug-free clinical...
by ASTCT
The following infographics are based on ASTCT's December 2, 2026 webinar in which Dr. Michael D. Jain (Moffitt Cancer Center) and Dr. Stephen Gottschalk (St. Jude Children’s...
by Alex Kadhim
A recent ASTCT webinar held on December 2, 2025 discussed innovations in CAR T for adult and pediatric patients, highlighting how CAR T-cell therapy is maturing into a therapy defined not only by...